5 reports

  • AN OVERVIEW OF THE CGVHD CLINICAL TRIALS, 2015

RITUXAN IS CURRENTLY IN DEVELOPMENT FOR THE TREATMENT OF DE-NOVO CGVHD IN TWO PHASE II TRIALS, ONE AT STANFORD UNIVERSITY AND THE OTHER AT NORTHSIDE HOSPITAL IN ATLANTA, GEORGIA, US (STANFORD UNIVERSITY, NCT##; NORTHSIDE HOSPITAL, NCT##).

  • Epidemiology
  • Hospital
  • Therapy
  • United States
  • Soligenix, Inc.

The prominent features of this report are - ##.

  • Clinical Trial
  • Hospital
  • World
  • Product Initiative
  • Soligenix, Inc.

The notes bear an interest rate of ##. ##% per annum, from and including June ##, 2018 and are payable semi-annually in arrears on January ## and July ## of each year, beginning on January ##, 2019.

  • Healthcare
  • Hospital
  • Pharmaceutical
  • Real Estate
  • Alexandria Real Estate Equities, Inc.

The notes bear an interest rate of ##. ##% per annum, from and including June ##, 2018 and are payable semi-annually in arrears on January ## and July ## of each year, beginning on January ##, 2019.

  • Healthcare
  • Hospital
  • Pharmaceutical
  • Real Estate
  • Alexandria Real Estate Equities, Inc.

The notes bear an interest rate of ##. ##% per annum, from and including June ##, 2018 and are payable semi-annually in arrears on January ## and July ## of each year, beginning on January ##, 2019.

  • Healthcare
  • Hospital
  • Pharmaceutical
  • Real Estate
  • Alexandria Real Estate Equities, Inc.